Type 2 diabetes in adults management evidence reviews for SGLT-2 inhibitors and GLP-1 mimetics
The aim of this report is to provide recommendations to supplement NICE technology appraisals 288, 315, 336 and 418 on canagliflozin, dapagliflozin, and empagliflozin, which are reproduced in the NICE guideline on type 2 diabetes management in adults (NG28)
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[London]
National Institute for Health and Care Excellence (UK)
2018, March 2018
|
| Edition: | Final |
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The aim of this report is to provide recommendations to supplement NICE technology appraisals 288, 315, 336 and 418 on canagliflozin, dapagliflozin, and empagliflozin, which are reproduced in the NICE guideline on type 2 diabetes management in adults (NG28) |
|---|---|
| Physical Description: | 1 PDF file (310 pages) illustrations |